Terms: = Lung cancer AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Treatment
56 results:
1. Computational markers for personalized prediction of outcomes in non-small cell lung cancer patients with brain metastases.
Benzekry S; Schlicke P; Mogenet A; Greillier L; Tomasini P; Simon E
Clin Exp Metastasis; 2024 Feb; 41(1):55-68. PubMed ID: 38117432
[TBL] [Abstract] [Full Text] [Related]
2. Impact of Commission on cancer Accreditation on cancer Survival: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis.
Ahmed A; Whittington J; Shafaee Z
Ann Surg Oncol; 2024 Apr; 31(4):2286-2294. PubMed ID: 38093167
[TBL] [Abstract] [Full Text] [Related]
3. Charcot neuroarthropathy in persons with diabetes: It's time for a paradigm shift in our thinking.
Wukich DK; Frykberg RG; Kavarthapu V
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3754. PubMed ID: 38069459
[TBL] [Abstract] [Full Text] [Related]
4. Silencing of CD147 inhibits cell proliferation, migration, invasion, lipid metabolism dysregulation and promotes apoptosis in lung adenocarcinoma via blocking the Rap1 signaling pathway.
Zhang N; Liu Z; Lai X; Liu S; Wang Y
Respir Res; 2023 Oct; 24(1):253. PubMed ID: 37880644
[TBL] [Abstract] [Full Text] [Related]
5. Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.
Granato G; Gesmundo I; Pedrolli F; Kasarla R; Begani L; Banfi D; Bruno S; Lopatina T; Brizzi MF; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Front Immunol; 2023; 14():1231363. PubMed ID: 37649486
[TBL] [Abstract] [Full Text] [Related]
6. Is Sarcomatoid lung cancer Associated With Inferior Overall Survival? A National cancer Database Analysis.
Poston LM; Bassiri A; Jiang B; Boutros C; Sinopoli J; Tapias Vargas L; Linden PA; Towe CW
J Surg Res; 2023 Nov; 291():380-387. PubMed ID: 37516045
[TBL] [Abstract] [Full Text] [Related]
7. Preoperative serum bilirubin is an independent prognostic factor for curatively resected esophageal squamous cell carcinoma.
Huang X; Chen Y; Yang H; Wang R; Chen Z
BMC Cancer; 2023 Jul; 23(1):706. PubMed ID: 37507653
[TBL] [Abstract] [Full Text] [Related]
8. Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines.
Yan M; Louie AV; Kotecha R; Ashfaq Ahmed M; Zhang Z; Guckenberger M; Kim MS; Lo SS; Scorsetti M; Tree AC; Sahgal A; Slotman BJ
Lung Cancer; 2023 Aug; 182():107281. PubMed ID: 37393758
[TBL] [Abstract] [Full Text] [Related]
9. Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid Tumors.
Liu Y; Mullangi S; Debono D; Chen X; Pham T; Fisch MJ; Gordon AS; Hershman DL
JCO Oncol Pract; 2023 Sep; 19(9):731-740. PubMed ID: 37384847
[TBL] [Abstract] [Full Text] [Related]
10. Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective treatment of Chemoresistance in Non-Small Cell lung cancer.
Dera AA; Zaib S; Areeba ; Hussain N; Rana N; Javed H; Khan I
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375404
[TBL] [Abstract] [Full Text] [Related]
11. Germline Genetic Testing After cancer Diagnosis.
Kurian AW; Abrahamse P; Furgal A; Ward KC; Hamilton AS; Hodan R; Tocco R; Liu L; Berek JS; Hoang L; Yussuf A; Susswein L; Esplin ED; Slavin TP; Gomez SL; Hofer TP; Katz SJ
JAMA; 2023 Jul; 330(1):43-51. PubMed ID: 37276540
[TBL] [Abstract] [Full Text] [Related]
12. Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).
Niimura T; Miyata K; Hamano H; Nounin Y; Unten H; Yoshino M; Mitsuboshi S; Aizawa F; Yagi K; Koyama T; Goda M; Kanda Y; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
Drug Saf; 2023 Jun; 46(6):545-552. PubMed ID: 37106270
[TBL] [Abstract] [Full Text] [Related]
13. Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics.
Zhou S; Sha B; Wang L; Zhao Y; Wang Z; Zhang X; Han L; Shao F; Chen X
Xenobiotica; 2023 Feb; 53(2):84-92. PubMed ID: 36821249
[TBL] [Abstract] [Full Text] [Related]
14. Cytoprotective, Antiproliferative, and Anti-Oxidant Potential of the Hydroethanolic Extract of
Alvarez-Ortega N; Caballero-Gallardo K; Juan C; Juan-Garcia A; Olivero-Verbel J
Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668856
[No Abstract] [Full Text] [Related]
15. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract] [Full Text] [Related]
16. Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial.
Meduri B; Baldissera A; Iotti C; Scheijmans LJEE; Stam MR; Parisi S; Boersma LJ; Ammendolia I; Koiter E; Valli M; Scandolaro L; Busz D; Stenfert Kroese MC; Ciabatti S; Giacobazzi P; Ruggieri MP; Engelen A; Munafò T; Westenberg AH; Verhoeven K; Vicini R; D'Amico R; Lohr F; Bertoni F; Poortmans P; Frezza GP
J Clin Oncol; 2023 Apr; 41(12):2201-2210. PubMed ID: 36623246
[TBL] [Abstract] [Full Text] [Related]
17. An RNA-seq transcriptome analysis for investigating the anti-lung cancer activity of medicinal
Maimaiti A; Xu J; Shi L
Br J Nutr; 2023 Sep; 130(5):737-749. PubMed ID: 36468438
[No Abstract] [Full Text] [Related]
18. Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study.
Lauppe R; Nilsson FOL; Fues Wahl H; Lilja M; Vikström A; T Asanin S
Acta Oncol; 2022 Nov; 61(11):1354-1361. PubMed ID: 36368902
[TBL] [Abstract] [Full Text] [Related]
19. Investigation of radiomics based intra-patient inter-tumor heterogeneity and the impact of tumor subsampling strategies.
Henry T; Sun R; Lerousseau M; Estienne T; Robert C; Besse B; Robert C; Paragios N; Deutsch E
Sci Rep; 2022 Oct; 12(1):17244. PubMed ID: 36241749
[TBL] [Abstract] [Full Text] [Related]
20. Predictors of Secondary lung cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis.
Alnimer Y; Ali MKM
Clin Lung Cancer; 2022 Dec; 23(8):e510-e518. PubMed ID: 36008241
[TBL] [Abstract] [Full Text] [Related]
[Next]
